These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 23522341)

  • 21. Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin.
    Nakamura H;
    Atheroscler Suppl; 2007 Aug; 8(2):13-7. PubMed ID: 17586102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
    Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
    Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Screening for hyperlipidemia in cardiovascular high-risk patients in austrian diabetes ambulances].
    Brath H; Wascher TC; Kästenbauer T; Toplak H
    MMW Fortschr Med; 2012 Jun; 154 Suppl 2():41-7. PubMed ID: 23424754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly].
    MMW Fortschr Med; 2005 Aug; 147(33-34):50-1. PubMed ID: 16138640
    [No Abstract]   [Full Text] [Related]  

  • 25. Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment.
    Lahoz C; Peña R; Mostaza JM; Laguna F; García-Iglesias MF; Taboada M; Pintó X
    Metabolism; 2005 Jun; 54(6):741-7. PubMed ID: 15931608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: a post hoc analysis of the MEGA Study.
    Nishiwaki M; Ikewaki K; Ayaori M; Mizuno K; Ohashi Y; Ohsuzu F; Ishikawa T; Nakamura H;
    J Cardiol; 2013 Mar; 61(3):196-200. PubMed ID: 23265677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Statin treatment in type 2 diabetes. Is it a must today?].
    Faust M
    MMW Fortschr Med; 2003 Feb; 145(9):35-6. PubMed ID: 12666527
    [No Abstract]   [Full Text] [Related]  

  • 28. Early Improvements in insulin sensitivity and inflammatory markers are induced by pravastatin in nondiabetic subjects with hypercholesterolemia.
    Lee WJ; Lee WL; Tang YJ; Liang KW; Chien YH; Tsou SS; Sheu WH
    Clin Chim Acta; 2008 Apr; 390(1-2):49-55. PubMed ID: 18201563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between lowering low-density lipoprotein cholesterol with pravastatin and primary prevention of cardiovascular disease in mild to moderate hypercholesterolemic Japanese.
    Teramoto T; Nakaya N; Yokoyama S; Ohashi Y; Mizuno K; Nakamura H;
    J Atheroscler Thromb; 2010 Aug; 17(8):879-87. PubMed ID: 20543522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
    Strony J; Hoffman R; Hanson M; Veltri E
    Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Achieving lipid goals in real life: the Dutch DISCOVERY study.
    Bots AF; Kastelein JJ;
    Int J Clin Pract; 2005 Dec; 59(12):1387-94. PubMed ID: 16351669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control.
    Gardner SF; Marx MA; White LM; Granberry MC; Skelton DR; Fonseca VA
    Ann Pharmacother; 1997 Jun; 31(6):677-82. PubMed ID: 9184704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS).
    Lim PO; Yee KM
    Circulation; 1999 Aug; 100(6):686. PubMed ID: 10441109
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein (a) in patients with non-insulin dependent diabetes mellitus.
    Umeda F; Watanabe J; Inoue K; Hisatomi A; Mimura K; Yamauchi T; Sako Y; Kunisaki M; Tajiri Y; Nawata H
    Endocrinol Jpn; 1992 Feb; 39(1):45-50. PubMed ID: 1535040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
    Devroey D; Velkeniers B; Duquet W; Betz W
    Int J Cardiol; 2005 May; 101(2):231-5. PubMed ID: 15882669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Marked decrease in serum HDL cholesterol levels by combined probucol-pravastatin treatment in hypercholesterolemic NIDDM patients.
    Ikeda T
    Diabetes Care; 1993 May; 16(5):849-50. PubMed ID: 8495635
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of pravastatin on erythrocyte rheological and biochemical properties in poorly controlled Type 2 diabetic patients.
    Miossec P; Zkhiri F; Pariès J; David-Dufilho M; Devynck MA; Valensi PE
    Diabet Med; 1999 May; 16(5):424-30. PubMed ID: 10342343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Type 2 diabetic: risk same as after infarct. With LDL not only the quantity counts].
    MMW Fortschr Med; 2004 Jun; 146(24):4. PubMed ID: 15366509
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.